Pluripotent Stem Cell‑Derived Vascular Endothelial Lineage

Vascular endothelial cells are the core functional cells that constitute systemic microcirculation, regulate angiogenesis, and maintain tissue perfusion. They serve as essential experimental resources in applications including ischemic injury repair, artificial blood vessel construction, tissue‑engineered organ development, and vascular toxicity drug screening. Traditional research relies mainly on human umbilical vein endothelial cells (HUVECs), which face major limitations such as restricted tissue availability, limited in vitro expansion capacity, high batch‑to‑batch variability, and difficulty in standardized large‑scale production. Meanwhile, mouse embryonic stem cell‑based endothelial differentiation systems exhibit significant species differences from human vascular developmental regulatory pathways, limiting the direct translation of experimental findings into human‑related research and development, and restricting progress in vascular product development and mechanism studies.

In 2002, Robert Langer's team at MIT published a landmark study that established the first standardized technology platform for complete induction, purification, and functional validation of endothelial lineage cells derived from human embryonic stem cells (H9 cell line). This approach induced spontaneous differentiation of human pluripotent stem cells by removing pluripotency maintenance factors and promoting suspension formation of embryoid bodies (EBs). The optimal window for endothelial cell enrichment occurred between differentiation days 13–15, during which endothelial‑specific genes including PECAM1, VE‑cadherin, and CD34 reached peak expression levels, and capillary‑like vascular networks spontaneously formed within embryoid bodies.

The study demonstrated that high‑purity human embryonic endothelial cells could be isolated through PECAM1‑based flow cytometric sorting. The purified cells exhibited molecular characteristics highly similar to mature HUVECs and possessed typical endothelial functions, including acetylated LDL (ac‑LDL) uptake capacity. In Matrigel assays, these cells were capable of self‑organizing into vascular networks with closed luminal structures. Furthermore, in vivo transplantation studies demonstrated that when these endothelial cells were incorporated into biodegradable biomaterial scaffolds and implanted into immunodeficient mice, they generated functional microvascular networks that connected with host human vasculature. The newly formed vessels were able to support normal blood flow, providing strong evidence for their potential in vascular regeneration.

This system overcame the limitations of primary endothelial cell supply by enabling the unlimited and homogeneous production of human endothelial cells in vitro. It also revealed fundamental differences between human and mouse endothelial developmental gene expression patterns, establishing a standardized paradigm for human vascular research. Based on this classical differentiation technology, pluripotent stem cell‑derived endothelial cell production platforms are now widely applied in cell therapy development for ischemic diseases, artificial vascular tissue engineering, vascularization of large‑scale engineered tissues, and cardiovascular drug vascular safety evaluation. These platforms provide stable, reproducible, and standardized human cell solutions for vascular biology research and clinical translation.

Using hESCs/iPSCs, human vascular endothelial cells with angiogenic capacity can be generated through a vascular lineage induction process involving mesoderm formation, vascular progenitor establishment, endothelial cell maturation, and functional validation. PSC‑derived endothelial cells provide stable and expandable human cellular resources for vascular disease modeling, drug screening, tissue engineering, and regenerative medicine research.